John Ouyang

6.8k citations

67 papers · 4.9k indexed · 2 hit papers · h-index 31

Impact in

Nephrology top 0.5%
Genetics top 0.5%
- Genetic and Kidney Cyst Diseases
- Genetic Syndromes and Imprinting

Papers in ⓘ

Nephrology 9
- Renal Diseases and Glomerulopathies 6
Critical Care and Intensive Care Medicine 6

Co-authors: Frank S. Czerwiec (29 shared papers)Vicente E. Torres (25 shared papers)Arlene B. Chapman (24 shared papers)Ronald D. Perrone (19 shared papers)Olivier Devuyst (16 shared papers)Ron T. Gansevoort (19 shared papers)Holly B. Krasa (15 shared papers)Eiji Higashihara (12 shared papers)
Journals: Kidney International Reports (7 papers)Nephrology Dialysis Transplantation (7 papers)Journal of Cardiac Failure (4 papers)Journal of the American Society of Nephrology (4 papers)Journal of the American College of Cardiology (4 papers)
Partner nations: United States Netherlands Japan

In The Last Decade

John Ouyang

66 papers receiving 4.8k citations

Hit Papers

align trajectories log scale

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease 2017 · 398 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2012 New England Journal of Medicine

Peers

Countries citing papers authored by John Ouyang

Since Specialization

Citations

This map shows the geographic impact of John Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ouyang more than expected).

Fields of papers citing papers by John Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ouyang. The network helps show where John Ouyang may publish in the future.

Co-authors

The 25 scholars most cited alongside John Ouyang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Ouyang Line = papers co-authored together John Ouyang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease New England Journal of Medicine ·Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec Hit paper breakdown →	2012	1071
2	Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease New England Journal of Medicine ·Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Gary G. Koch, John Ouyang, Robert D. McQuade, Jaime D. Blais, Frank S. Czerwiec, Olga Sergeyeva Hit paper breakdown →	2017	398
3	Vasopressin V ₂ -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Circulation ·Mihai Gheorghiade, Imran Khan Niazi, John Ouyang, Frank S. Czerwiec, Jun‐ichi Kambayashi, Manuela Zampino, Cesare Orlandi	2003	338
4	Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia Journal of the American Society of Nephrology ·Tomás Berl, Friederike Quittnat-Pelletier, Joseph G. Verbalis, Robert W. Schrier, Daniel G. Bichet, John Ouyang, Frank S. Czerwiec	2010	237
5	Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure American Journal of Physiology-Renal Physiology ·Lisa C. Costello‐Boerrigter, William B. Smith, Guido Boerrigter, John Ouyang, Christopher A. Zimmer, Cesare Orlandi, John C. Burnett	2005	207
6	Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database Drug Safety ·Paul B. Watkins, James H. Lewis, Neil Kaplowitz, David Alpers, Jaime D. Blais, Dan M. Smotzer, Holly B. Krasa, John Ouyang, Vicente E. Torres, Frank S. Czerwiec, Christopher A. Zimmer	2015	141
7	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial American Journal of Psychiatry ·Christoph U. Correll, Aleksandar Skuban, John Ouyang, Mary Hobart, Stephanie Pfister, Robert D. McQuade, Margaretta Nyilas, William H. Carson, Raymond Sanchez, Hans Eriksson	2015	140
8	Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction Journal of the American College of Cardiology ·James E. Udelson, Cesare Orlandi, John Ouyang, Holly B. Krasa, Christopher A. Zimmer, Geir Frivold, W. Herbert Haught, Sheiba Meymandi, Cezar Macarie, Dimitar Raef, Patricia Wedge, Marvin A. Konstam, Mihai Gheorghiade	2008	139
9	A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia Schizophrenia Research ·John M. Kane, Aleksandar Skuban, John Ouyang, Mary Hobart, Stephanie Pfister, Robert D. McQuade, Margaretta Nyilas, William H. Carson, Raymond Sanchez, Hans Eriksson	2015	137
10	Prognostic Value of Blood Urea Nitrogen in Patients Hospitalized With Worsening Heart Failure: Insights From the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) Study Journal of Cardiac Failure ·Gerasimos Filippatos, Joseph S. Rossi, Donald M. Lloyd‐Jones, Wendy Gattis Stough, John Ouyang, David Shin, Christopher M. O’Connor, Kirkwood F. Adams, Cesare Orlandi, Mihai Gheorghiade	2007	130
11	Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial Nephrology Dialysis Transplantation ·Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Ann Dandurand, John Ouyang, Frank S. Czerwiec, Jaime D. Blais, (unknown)	2017	127
12	Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial Acute Cardiac Care ·Joseph S. Rossi, Melike Bayram, James E. Udelson, Donald M. Lloyd‐Jones, Kirkwood F. Adams, Christopher M. O’Connor, Wendy Gattis Stough, John Ouyang, David Shin, Cesare Orlandi, Mihai Gheorghiade	2007	123
13	Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Clinical Journal of the American Society of Nephrology ·Eiji Higashihara, Vicente E. Torres, Arlene B. Chapman, Jared J. Grantham, Kyongtae T. Bae, Terry Watnick, Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec	2011	120
14	Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia The American Journal of Cardiology ·Mihai Gheorghiade, Stephen S. Gottlieb, James E. Udelson, Marvin A. Konstam, Frank S. Czerwiec, John Ouyang, Cesare Orlandi	2006	114
15	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial Clinical Journal of the American Society of Nephrology ·Vicente E. Torres, Eiji Higashihara, Olivier Devuyst, Arlene B. Chapman, Ronald T. Gansevoort, Jared J. Grantham, Ronald D. Perrone, John Ouyang, Jaime D. Blais, Frank S. Czerwiec, (unknown)	2016	114
16	Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan Journal of Cardiac Failure ·Paul J. Hauptman, John C. Burnett, Mihai Gheorghiade, Liliana Grinfeld, Marvin A. Konstam, Dušan Kostić, Holly B. Krasa, Aldo P. Maggioni, John Ouyang, Karl Swedberg, Faı̈ez Zannad, Chris Zimmer, James E. Udelson	2013	107
17	Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease Kidney International ·María V. Irazabal, Vicente E. Torres, Marie C. Hogan, James F. Glockner, Bernard F. King, Troy G. Ofstie, Holly B. Krasa, John Ouyang, Frank S. Czerwiec	2011	101
18	Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study American Journal of Kidney Diseases ·Vicente E. Torres, Esther Meijer, Kyongtae T. Bae, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John Ouyang, Frank S. Czerwiec	2011	100
19	Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study The International Journal of Neuropsychopharmacology ·W. Wolfgang Fleischhacker, Mary Hobart, John Ouyang, Andrew Forbes, Stephanie Pfister, Robert D. McQuade, William H. Carson, Raymond Sanchez, Margareta Nyilas, Emmanuelle Weiller	2016	67
20	Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function American Journal of Kidney Diseases ·Wendy E. Boertien, Esther Meijer, Paul E. de Jong, Gert J. Ter Horst, Remco J. Renken, Eric J. van der Jagt, Peter Kappert, John Ouyang, Gerwin E. Engels, Willem van Oeveren, Joachim Struck, Frank S. Czerwiec, Dorothee Oberdhan, Holly B. Krasa, Ron T. Gansevoort	2015	66

About John Ouyang

John Ouyang is a scholar working on Nephrology, Critical Care and Intensive Care Medicine, Genetics, Psychiatry and Mental health and Pulmonary and Respiratory Medicine, having authored 67 papers that have together received 4.9k indexed citations. Recurring topics across this work include Genetic and Kidney Cyst Diseases (30 papers), Electrolyte and hormonal disorders (21 papers), Ion Transport and Channel Regulation (14 papers), Schizophrenia research and treatment (11 papers), Heart Failure Treatment and Management (9 papers), Cerebrospinal fluid and hydrocephalus (6 papers), Genetic Syndromes and Imprinting (6 papers) and Renal Diseases and Glomerulopathies (6 papers). The work is most often cited by research in Nephrology (895 citations), Genetics (2.2k citations), Pulmonary and Respiratory Medicine (1.9k citations), Psychiatry and Mental health (673 citations) and Pathology and Forensic Medicine (753 citations). John Ouyang has collaborated with scholars based in United States, Netherlands and Japan. Frequent co-authors include Frank S. Czerwiec, Vicente E. Torres, Arlene B. Chapman, Ronald D. Perrone, Olivier Devuyst, Ron T. Gansevoort, Holly B. Krasa, Eiji Higashihara, Cesare Orlandi and Jared J. Grantham. Their work appears in journals such as Kidney International Reports, Nephrology Dialysis Transplantation, Journal of Cardiac Failure, Journal of the American Society of Nephrology and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact